Evidence map›Paper›PMID 33945526›Full record

Trial reportPLoS medicine2021

Financial incentives and deposit contracts to promote HIV retesting in Uganda: A randomized trial.

Gabriel Chamie, Dalsone Kwarisiima, Alex Ndyabakira, Kara Marson, Carol S Camlin, Diane V Havlir, Moses R Kamya, Harsha Thirumurthy

2 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PLoS medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01864603 nacompletednot on this map

Sustainable East Africa Research in Community Health

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2021Enrolled150,395ConditionsHIV, Tuberculosis, Hypertension, DiabetesArmsUniversal ART in a streamlined care model, Annual Community Health Campaigns, Targeted PrEP and Targeted testing interventions, Baseline community-based HIV and multi-disease testing
NCT02890459 nacompletednot on this map

Innovative Incentive Strategies for Sustainable HIV Testing and Antiretroviral Treatment

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2020Enrolled3,580ConditionsHIV/AIDSArmsPrize incentive - Low, Prize incentive - High, Escalating payment incentive, Travel Voucher, Standard care
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gabriel ChamieUniversity of California, San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-5860-8081
Dalsone KwarisiimaInfectious Diseases Research Collaboration, Kampala, Uganda.
Alex NdyabakiraInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID 0000-0002-8420-462X
Kara MarsonUniversity of California, San Francisco, San Francisco, California, United States of America.
Carol S CamlinUniversity of California, San Francisco, San Francisco, California, United States of America.ORCID 0000-0001-5615-1164
Diane V HavlirUniversity of California, San Francisco, San Francisco, California, United States of America.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Harsha ThirumurthyCenter for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-3308-7603

Funding

Secondary distribution of HIV self-tests: an innovative strategy for promoting male partner testing and reducing riskR01MH111602 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THIRUMURTHY, HARSHA · 2016 to 2020
$3.2M
Innovative incentive strategies for sustainable HIV testing and linkage to careR01MH105254 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAMIE, GABRIEL, THIRUMURTHY, HARSHA · 2015 to 2019
$3.0M
NIMH NIH HHS R01 MH105254NIMH NIH HHS R01 MH111602
6 · The paper itself

Abstract

backgroundFrequent retesting for HIV among persons at increased risk of HIV infection is critical to early HIV diagnosis of persons and delivery of combination HIV prevention services. There are few evidence-based interventions for promoting frequent retesting for HIV. We sought to determine the effectiveness of financial incentives and deposit contracts in promoting quarterly HIV retesting among adults at increased risk of HIV. METHODS AND

findingsIn peri-urban Ugandan communities from October to December 2018, we randomized HIV-negative adults with self-reported risk to 1 of 3 strategies to promote HIV retesting: (1) no incentive; (2) cash incentives (US$7) for retesting at 3 and 6 months (total US$14); or (3) deposit contracts: participants could voluntarily deposit US$6 at baseline and at 3 months that would be returned with interest (total US$7) upon retesting at 3 and 6 months (total US$14) or lost if participants failed to retest. The primary outcome was retesting for HIV at both 3 and 6 months. Of 1,482 persons screened for study eligibility following community-based recruitment, 524 participants were randomized to either no incentive (N = 180), incentives (N = 172), or deposit contracts (N = 172): median age was 25 years (IQR: 22 to 30), 44% were women, and median weekly income was US$13.60 (IQR: US$8.16 to US$21.76). Among participants randomized to deposit contracts, 24/172 (14%) made a baseline deposit, and 2/172 (1%) made a 3-month deposit. In intent-to-treat analyses, HIV retesting at both 3 and 6 months was significantly higher in the incentive arm (89/172 [52%]) than either the control arm (33/180 [18%], odds ratio (OR) 4.8, 95% CI: 3.0 to 7.7, p < 0.001) or the deposit contract arm (28/172 [16%], OR 5.5, 95% CI: 3.3 to 9.1, p < 0.001). Among those in the deposit contract arm who made a baseline deposit, 20/24 (83%) retested at 3 months; 11/24 (46%) retested at both 3 and 6 months. Among 282 participants who retested for HIV during the trial, three (1%; 95%CI: 0.2 to 3%) seroconverted: one in the incentive group and two in the control group. Study limitations include measurement of retesting at the clinic where baseline enrollment occurred, only offering clinic-based (rather than community-based) HIV retesting and lack of measurement of retesting after completion of the trial to evaluate sustained retesting behavior.

conclusionsOffering financial incentives to high-risk adults in Uganda resulted in significantly higher HIV retesting. Deposit contracts had low uptake and overall did not increase retesting. As part of efforts to increase early diagnosis of HIV among high-risk populations, strategic use of incentives to promote retesting should receive greater consideration by HIV programs.

trial registrationclinicaltrials.gov: NCT02890459.

Indexed as

AdultFemaleHIV InfectionsHIV TestingHumansMaleMass ScreeningMiddle AgedMotivationRisk FactorsUgandaUrban PopulationYoung Adult

Identifiers

PMID33945526
PMCPMC8131095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.